21 results about "Fatty acid-binding protein" patented technology

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

This specification discloses FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases that highly express any of these FABPs, including cancers, particularly triple-negative breast cancer (TNBC), and other pro-inflammatory diseases, including cardiovascular diseases, obesity or obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune disorders, pain, and dementia. This specification also discloses methods for preparing the disclosed compounds.

The invention provides a biomarker combination for evaluating the progress of abdominal aortic aneurysm based on an adventitia and application of the biomarker combination, and the biomarker combination comprises at least two biomarkers selected from the following three independent groups, the at least two markers are from the same group or different groups: a myofibroblast transformation marker group: alpha-smooth muscle actin, monocyte chemotactic protein 1 and a tissue metalloproteinase inhibitor 1; the lipid metabolism related biomarker group comprises a lipid metabolism related protein CD36, carnitine palmitoyl transferase 1 and a fatty acid binding protein 4; and an inflammatory factor related biomarker group: IL-6, MCP-1 and TIMP1. According to the biological marker combination for evaluating the progress of the abdominal aortic aneurysm based on the adventitia, multi-channel biological markers are systematically integrated, an innovative tool is provided for accurate diagnosis, drug screening and curative effect monitoring of AAA, and meanwhile, an important foundation is laid for developing a collaborative treatment strategy based on adventitia fibroblast regulation.

This invention relates to the application of fatty acid-binding protein 4 (FABP4) inhibitors in the treatment of heart failure with preserved ejection fraction. Specifically, the application involves the oral administration of the fatty acid-binding protein 4 (FABP4) inhibitor BMS309403 for the prevention and / or treatment of heart failure with preserved ejection fraction.

The present invention relates to a veterinary vaccine composition based on fatty-acid-binding proteins (FABP) from parasites. Specifically, the invention discloses a veterinary vaccine composition based on the Schistosoma mansoni protein (rSm14) or homologous proteins of Fasciola hepatica (FhFABPs) that provide a homogeneous, long-term immune response against parasitic worms. The invention is also intended to provide a method for treating and preventing infection caused by parasitic worms, in particular Fasciola hepatica, and also the use of these proteins in a vaccine composition against parasitic worms.

The application provides a use of a compound BMS309403 in preparation of a medicament for preventing and treating acute hepatopancreas necrosis disease of prawns, and belongs to the technical field of prawn disease prevention and treatment. It is unexpectedly found that an inhibitor of a fatty acid binding protein LvFABP of Litopenaeus vannamei, i.e. the compound BMS309403, can be effectively applied in the prevention and treatment of AHPND, which can not only reduce the disease of hepatopancreas and intestinal tract of prawns, but also effectively reduce the Vibrio virulence gene copy number of hepatopancreas of diseased prawns, so that the survival rate of prawns infected with acute hepatopancreas necrosis disease can be significantly improved. In addition, as a small molecule compound, the BMS309403 is more superior to small molecule double-stranded RNA in synthesis, preservation and use, and therefore can have a better prospect in the actual production application of AHPND prevention and treatment.

Disclosed herein are FABP inhibitor compounds and their use in pharmaceutical compositions for the treatment of diseases, including cancers that highly express any of FABP, particularly triple negative breast cancer (TNBC), and other inflammation-inducing diseases, including cancer that highly express any of FABP. Comprise cardiovascular diseases, obesity or obesity-related diseases, diabetes, dyslipidemia, impaired blood glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune diseases, pain and dementia. Also disclosed herein are methods for preparing the disclosed compounds.

The invention belongs to the technical field of biological medicine, and particularly provides a medicine for controlling female menopausal body weight, which comprises a fatty acid binding protein 4 inhibitor or pharmaceutically acceptable salt thereof. The medicine for controlling the weight of women in the menopausal period has the effect of controlling the weight of women in the menopausal period and can relieve the obesity of women in the menopausal period. The medicine is a non-hormone medicine, does not have the risk of inducing hormone tumors by regulating the effects of hormones and related pathways, can be orally taken, does not need to be injected, and has the characteristic of convenience in administration.

In the body, adipose tissue is comprised of adipocytes as well as various other cell types, including immune cells, that may contribute to the overall extracellular vesicle pool. Adiponectin, a protein hormone produced by fat cells, and fatty acid binding protein 4 (FABP4) were selected as markers to isolate adipocyte- specific EVs / adipomes from the total pool of white adipose tissue-derived EVs based on in vitro data showing that they colocalized with Annexin V, an apoptosis marker, on the surface of budding apoptotic bodies. Intact L-adipomes (large- adipomes) and S-adipomes (small-adipomes) were successfully and selectively enriched from large-EVs and small-EVs, respectively. Immunoblotting analysis confirmed the presence of adiponectin, FABP4, Annexin V, and perilipin in both L- and S-adipomes, providing further evidence of their adipocyte origin.

The invention provides a preparation method of an intestinal fatty acid binding protein IFABP antigen, which comprises the following steps: S1, designing a mature peptide into a signal peptide-6 * His-linker peptide-IFABP-linker peptide-IFABP-YINK-containing signal peptide dimer protein based on a gene sequence of an NCBI (National Center of Biotechnology Information) login number NP000125.2 encoding human IFABP mature peptide, and performing codon optimization on an amino acid sequence of the signal peptide-6 * His-linker peptide-IFABP-linker peptide-IFABP-YINK to obtain a nucleic acid sequence; s2, cloning the optimized gene into a eukaryotic expression vector, and constructing a recombinant expression plasmid; and S3, transfecting the recombinant plasmid into a mammalian cell 293F, carrying out cell culture after transfection, and purifying to obtain the IFABP antigen. According to the preparation method, the high-purity and high-activity IFABP recombinant antigen can be efficiently obtained on a large scale, and then the high-performance anti-IFABP monoclonal antibody is obtained.

The present disclosure contemplates detecting and treating a pathological condition, such as intestinal ischemia such as acute mesenteric ischemia, necrotizing enterocolitis, inflammatory bowel disease, and bowel graft rejection in a subject's intestinal tract. The methodology comprises obtaining a sample from the subject; detecting whether an analyte such as Villin-1, α-glutathione S-transferase, or intestinal fatty acid binding protein (I-FABP) is present in the sample by contacting the sample with an anti-analyte antibody and detecting binding between analyte and the antibody; and diagnosing the subject with the condition when, for example, the presence of analyte in the sample is detected and exceeds the level of analyte in a healthy control sample. A superparamagnetic bead includes an anti-Villin-1 antibody; an anti-α-glutathione S-transferase antibody, or an anti-intestinal-fatty acid binding protein (I-FABP) antibody. A superparamagnetic bead comprising a surface coating that binds Villin-1, α-glutathione S-transferase, or intestinal-fatty acid binding protein (I-FABP).

Disclosed herein are purified enantiomers isolated from racemic 3-(2,3-dihydro-1H-inden-2-yloxycarbonyl)-2,4-di(2-methoxyphenyl)cyclobutane-1-carboxylic acid useful for treating pain, neurological diseases, anxiety, arthritis, skin disorders, spinal cord injuries, psoriasis, metabolic disorders, and cancer.

A class of compounds that bind to fatty acid binding protein (FABP4) and modulate adipocyte metabolism to drive enhanced glucose utilization, as well as pharmaceutical compositions comprising such compounds in combination with a pharmaceutically acceptable diluent or carrier, and optionally further in combination with a therapeutically active agent, in particular to pharmaceutical compositions comprising such compounds. And the use of these compounds in medicine and for the preparation of medicaments for the treatment of diseases acting on FABP4. # imgabs0 #

A method for wound treatment includes administering a subject in need thereof with a pharmaceutical composition. The pharmaceutical composition includes: an effective amount of a fatty acid-binding protein 4 (FABP4) antagonist and / or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The wound treatment may include promoting wound angiogenesis, enhancing wound healing, reducing wound inflammation, and / or inhibiting wound scarring.

Disclosed herein are FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases including cancers that highly express any of these FABPs, in particular triple-negative breast cancer (TNBC), hepatocellular carcinoma and other inflammation-induced diseases including cardiovascular disease, obesity or an obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting glucose, vitiligo, psoriasis, viral infection, pain and dementia. Also disclosed herein are methods for preparing the disclosed compounds.

The invention belongs to the technical field of biological medicine, and particularly relates to application of a fatty acid binding protein 4 inhibitor or pharmaceutically acceptable salt thereof in preparation of a medicine for treating or preventing osteoporosis, the in-vivo anti-osteoporosis activity of the fatty acid binding protein 4 inhibitor is similar to that of a clinical medicine alendronate sodium, but the chemical structure of the fatty acid binding protein 4 inhibitor does not belong to bisphosphate. Therefore, the composition is suitable for osteoporosis patients intolerant to bisphosphate drugs. The pharmacological action mechanism of the compound does not involve regulation and control of hormones and related pathways, and the risk of inducing hormone tumors does not exist, so that the compound is suitable for osteoporosis patients with high risk of hormone tumors.

In the body, adipose tissue is comprised of adipocytes as well as various other cell types, including immune cells, that may contribute to the overall extracellular vesicle pool. Adiponectin, a protein hormone produced by fat cells, and fatty acid binding protein 4 (FABP4) were selected as markers to isolate adipocyte-specific EVs / adipomes from the total pool of white adipose tissue-derived EVs based on in vitro data showing that they colocalized with Annexin V, an apoptosis marker, on the surface of budding apoptotic bodies. Intact L-adipomes (large-adipomes) and S-adipomes (small-adipomes) were successfully and selectively enriched from large-EVs and small-EVs, respectively. Immunoblotting analysis confirmed the presence of adiponectin, FABP4, Annexin V, and perilipin in both L- and S-adipomes, providing further evidence of their adipocyte origin.

Disclosed herein are FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases including cancers that highly express any of these FABPs, in particular triple-negative breast cancer (TNBC), hepatocellular carcinoma and other inflammation-induced diseases including cardiovascular disease, obesity or an obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting glucose, vitiligo, psoriasis, viral infection, pain and dementia. Also disclosed herein are methods for preparing the disclosed compounds.

The invention discloses a yang-warming and kidney-tonifying paste patch for preventing diabetes from being converted into diabetic kidney and a preparation method thereof. The traditional Chinese medicine ointment patch is prepared from traditional Chinese medicines such as radix rehmanniae preparata, fructus evodiae, clove, cortex cinnamomi, radix codonopsis, radix puerariae and semen cuscutae, and is prepared by grinding the traditional Chinese medicines into powder, blending the powder into paste and preparing the paste into a cylindrical medicine cake. The traditional Chinese medicine composition acts on the Shenshu acupoint through acupoint application, and traditional Chinese medicine ingredients are used for regulating kidney qi and blood and protecting kidney functions. Clinical tests show that a test group using the application is remarkably superior to a control group in the aspect of improving the traditional Chinese medicine syndromes. The fatty acid binding protein 1 in the early kidney injury marker urine has the effects of regulating lipid metabolism and resisting oxidative stress, can protect renal tubule cells, and has the early kidney injury warning capability, and a test group applying the application has a remarkable effect of reducing the level of the fatty acid binding protein 1. Safety analysis shows that the application is low in adverse reaction occurrence rate and good in safety. The invention provides a traditional Chinese medicine non-drug therapy which has no gastrointestinal burden and is convenient for long-term persistence for preventing and treating the diabetic kidney disease.

A kind of heart-shaped fatty acid binding protein determination kit, including box, box cover, fixed seat, movable plate, sleeve, pull plate, mounting bracket, lock sleeve, the box hinge box cover, box cover connects lock tongue, box connects lock seat, lock tongue is adapted to lock seat, lock tongue connects lock seat, the inside connection fixed seat of box, fixed seat has slide, slide is adapted to movable plate, movable plate connects slide, movable plate slides in slide, movable plate has multiple top rods, fixed seat has multiple placement grooves, placement groove is adapted to top rod, top rod connects placement groove, top rod upper portion connects rubber top block, rubber top block connects reagent bottle, reagent bottle connects placement groove.

The invention provides a method for inhibiting MDSCs amplification, which comprises the following steps: (1) acquiring mouse bone marrow cells, and culturing by using a culture medium; and (2) adding an FABP4 inhibitor into the culture system in the step (1), uniformly mixing, and continuously culturing. Research finds that the FABP4 inhibitor with proper concentration is added into an MDSCs differentiation induction system for treatment, so that the generation of MDSCs can be obviously inhibited, and a corresponding methodology is established. The MDSCs inhibit the immune response under many pathological conditions, the accumulation of which is closely related to the adverse clinical outcomes of various diseases, including tumors. Therefore, the method for inhibiting the generation of the MDSCs can provide a methodological basis for pathogenesis research of MDSCs related diseases and development of targeted drugs, and provides a research basis for immunotherapy taking the MDSCs as a target spot.